RIGL RIGEL PHARMACEUTICALS INC

Nasdaq rigel.com


$ 41.40 $ -0.54 (-1.29 %)    

Monday, 17-Nov-2025 13:13:06 EST
QQQ $ 606.18 $ 0.05 (0.01 %)
DIA $ 469.77 $ -1.09 (-0.23 %)
SPY $ 669.08 $ -0.65 (-0.1 %)
TLT $ 89.16 $ 0.08 (0.09 %)
GLD $ 374.59 $ 0.60 (0.16 %)
$ 41.94
$ 41.80
$ 41.33 x 12
$ 41.50 x 500
$ 41.40 - $ 42.55
$ 14.63 - $ 43.72
714,498
na
761.27M
$ 1.04
$ 6.72
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-04-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-01-2023 06-30-2023 10-Q
11 05-02-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-02-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-05-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-01-2018 03-31-2018 10-Q
32 03-06-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-01-2017 06-30-2017 10-Q
35 05-02-2017 03-31-2017 10-Q
36 03-07-2017 12-31-2016 10-K
37 11-01-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-03-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rigel-pharmaceuticals-reports-publication-in-the-journal-of-hematology--oncology-5-year-data-showing-durable-efficacy-and-manageable-safety-for-rezlidhia-in-rr-midh1-aml

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mI...

 jefferies-upgrades-rigel-pharmaceuticals-to-buy-raises-price-target-to-42

Jefferies analyst Eun Yang upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) from Hold to Buy and raises the price target from $2...

 cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-38

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

 rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-210000m-220000m-to-285000m-290000m-vs-281095m-est

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 million to $285.000 million-$290...

 rigel-pharmaceuticals-q3-eps-146-beats-084-estimate-sales-69462m-beat-61880m-estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of...

 rigel-pharma-announces-first-patient-enrolled-in-dose-expansion-phase-of-ongoing-phase-1b-study-of-r2891-in-patients-with-rr-lower-risk-mds-earlier-today

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk...

 hc-wainwright--co-reiterates-buy-on-rigel-pharmaceuticals-maintains-57-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57...

 cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-32

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

 rigel-pharmaceuticals-q2-eps-328-beats-019-estimate-sales-101685m-beat-48142m-estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the analyst consensus estimate of...

 rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-200000m-210000m-to-210000m-220000m-vs-201095m-est

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $200.000 million-$210.000 million to $210.000 million-$220...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION